Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $624,027.20. This represents a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Thursday, April 30th, Houte Hans Van sold 2,388 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.65, for a total transaction of $39,760.20.

Nurix Therapeutics Stock Up 1.7%

Shares of NASDAQ:NRIX opened at $16.88 on Thursday. The firm has a market cap of $1.75 billion, a P/E ratio of -5.34 and a beta of 1.87. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $22.50. The company’s 50-day moving average price is $15.88 and its two-hundred day moving average price is $16.18.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Morgan Stanley set a $36.00 target price on Nurix Therapeutics and gave the company an “overweight” rating in a research note on Thursday, January 8th. Piper Sandler upped their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Stifel Nicolaus upped their target price on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.46.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors have recently made changes to their positions in NRIX. Larson Financial Group LLC increased its holdings in Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Nurix Therapeutics by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after buying an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $31,000. Royal Bank of Canada increased its stake in shares of Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock valued at $206,000 after acquiring an additional 1,623 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of Nurix Therapeutics by 8.2% in the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock valued at $417,000 after acquiring an additional 1,674 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.